Phase II Study of Sorafenib + Carboplatin and Docetaxel in First Line Treatment of Stage IIIB/IV NSCLC

Completed · Phase 2

Conditions studied: Non-Small Cell Lung Cancer

In brief

This is an open-label, single institution, phase II study of Sorafenib in combination with docetaxel and carboplatin in patients with advanced non-small cell lung cancer. Docetaxel and carboplatin will be given on day 1 of every three week cycle. Patients will take Sorafenib twice a day on the 1st day of treatment and continue to take the medication every day until progression of disease, prohibitive toxicity, or patient withdrawal from the study. Chemotherapy courses will repeat every 21 days in the absence of disease progression or unacceptable toxicity for a total of four cycles.

Key facts

Study ID

NCT00647426

Run by

Abramson Cancer Center at Penn Medicine

People needed

7

Starts

2007-11-01

Expected to finish

2012-12-01

Last updated by the study team

2019-10-22

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Histologically or cytologically confirmed NSCLC with clinical or radiological evidence of advanced disease (Stage IIIB/IV)
• Uni-dimensionally measurable disease
• Age => 18 years
• ECOG performance status of 0-1
• Life expectancy > 3 months

You may not qualify if…

• Small-cell or mixed histologies including a small cell component
• Prior chemotherapy, biotherapy, radiotherapy to an area of measurable disease
• Patients with peripheral neuropathy grade => 2

Where it is running

• Abramson Cancer Center of University of Pennsylvania — Philadelphia, Pennsylvania, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.